Your session is about to expire
← Back to Search
Daratumumab + Ibrutinib for Chronic Lymphocytic Leukemia
Study Summary
This trial tests the side effects and effectiveness of two drugs, daratumumab and ibrutinib, for treating patients with chronic lymphocytic leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have not received chemotherapy, immunotherapy or targeted therapy for CLL treatment before, except for local radiation or corticosteroids to relieve symptoms.You have experienced any of these symptoms for a certain period of time: losing more than 10% of your weight without trying, feeling very tired and unable to do normal activities, having a fever of 100.5 degrees Fahrenheit or higher for two weeks or more without an infection, or experiencing night sweats for more than a month without an infection.
- Group 1: Treatment (daratumumab, ibrutinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still openings for participants in this trial?
"This clinical trial is no longer recruiting participants, with the last edit being on August 22nd 2022. Currently, 1522 studies related to Chronic lymphocytic leukemia (CLL) are actively enrolling patients and 291 Pharmacological Study trials are searching for enrollees."
Are there any precedent investigations on Pharmacological Study?
"Currently, 291 clinical trials for Pharmacological Study are ongoing with 49 Phase 3 studies. While Karlsruhe and Quebec have a noteworthy number of these medical experiments taking place, there are 12,739 locations running some type of pharmacological trial."
What is the primary purpose of this experimentation?
"This research endeavour will span up to two years, with the purpose of assessing National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0-defined adverse events. Secondary outcomes include overall survival (summarized by Kaplan-Meier method), overall survival in complete remissions and partial responses accompanied by a 95% confidence interval, as well as progression-free survival summarized likewise by Kaplan-Meier methodology."
What is the aggregate figure of participants in this research project?
"Unfortunately, recruiting for this trial has now closed. It was initially posted on the 16th of August 2018 and last updated on the 22nd of August 2022. If you are hopeful to find other medical studies relevant to your condition, there are 1522 trials searching for participants with chronic lymphocytic leukemia (CLL) and 291 Pharmacological Studies actively enrolling patients."
What conditions tend to be treated with Pharmacological Study?
"Pharmacological Study is a popular treatment for biological response modifiers, but it has been used to address an array of other medical issues including refractory multiple myeloma, relapsed or refractory multiple myeloma, and cell transplants."
To what degree can participating in a Pharmacological Study be hazardous to someone's health?
"The safety of this pharmacological study has been evaluated at 1 on the scale due to Phase 1 testing, which implies that only preliminary data is available regarding efficacy and security."
Share this study with friends
Copy Link
Messenger